Crescentic glomerulonephritis (CrGN) with rapidly progressive renal function loss necessitates prompt pathology diagnosis and treatment. Non-invasive biomarkers are crucial in cases where renal biopsy is unavailable or unsuitable.
Product: Human Alcohol dehydrogenase 1C (ADH1C) ELISA Kit
Pub Date：2025-11-11 IF: 4.600
Environmental unpredictability challenges the transmission success of vector-borne parasites like Plasmodium, whose fitness depends on synchronizing the production of transmission forms, called gametocytes, with vector availability.
Product: Avian C-Reactive Protein (CRP) ELISA Kit
Pub Date：2025-11-05 IF: 3.000
Chelidonium majus l., a traditional herbal medicine listed in the Pharmacopoeia of China (2025), has remarkable anticancer properties. Chelidonine (CHE), its primary bioactive alkaloid, can inhibit the proliferation of breast cancer (BC) cells; however, whether its antitumor effect in BC is mediated through regulating M2 macrophage polarization remains unexplored.
Product: Human Interleukin-1 beta (IL1B) ELISA Kit Human Interleukin 6 (IL-6) ELISA Kit Rabbit Anti-Human CD206 Polyclonal Antibody
Pub Date：2025-10-31 IF: 8.300
Parkinson’s disease (PD) involves both mitochondrial dysfunction and Lewy body pathology. However molecular links between these features remain unclear. Here, we identify Presenilin-associated rhomboid-like protein (PARL) as a Lewy body component, RARL regulates mitochondrial apoptosis via interacting with orphan nuclear receptor Nur77.
Product: Human Presenilins-associated rhomboid-like protein, mitochondrial (PARL) ELISA Kit
Pub Date：2025-10-06 IF: 9.600
The incidence of certain types of extrahepatic cancers significantly increases in nonalcoholic fatty liver disease (NAFLD), the mechanisms of which are elusive.
Product: Mouse Receptor tyrosine-protein kinase erbB-4 (ERBB4) ELISA Kit Mouse Mitochondrial ribonuclease P protein 1 (RG9MTD1) ELISA Kit
Pub Date：2025-09-24 IF: 30.900
Triple-negative breast cancer (TNBC) urgently requires new therapeutic strategies due to the limited efficacy of conventional treatments. Recently, PANoptosis, an integrated form of apoptosis, necroptosis, and pyroptosis, has emerged as a promising target in cancer therapy, though effective agents remain scarce.
Product: Human High mobility group protein B1 (HMGB1) ELISA Kit
Pub Date：2025-08-22 IF: 6.600
电话: 
邮箱: 
地址: